A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma

This trial is testing a new drug called SHR2554 combined with chemotherapy as a first treatment for people who have just been diagnosed with peripheral T-cell lymphoma — a group of blood cancers that start in T cells, a type of immune cell. **You may be eligible if...** - You are between 18 and 70 years old - You have been newly diagnosed with peripheral T-cell lymphoma (confirmed by biopsy) - You have not yet received any chemotherapy or treatment for this lymphoma - You are in reasonably good health (ECOG performance status 0-1) with a life expectancy of at least 12 weeks - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have active hepatitis B or hepatitis C infection - You have a history of significant heart disease - You have had another cancer in the past 5 years - You are pregnant or breastfeeding - You had major surgery in the past 4 weeks Talk to your doctor to see if this trial is right for you.